Colgate-Palmolive enters its May 1 Q1 earnings report with one of the more unusual positioning setups in the consumer staples space right now: options sentiment has swung sharply to the bullish side even as the stock hovers near flat on the year.
The clearest shift is in options. The put/call ratio dropped to 0.95, more than two standard deviations below its 20-day average of 1.27 — the lowest reading in the past year. For a stock that spent most of March and early April with a PCR above 1.40, that reversal is striking. It suggests traders are no longer seeking downside protection at the same rate they were during the tariff-driven uncertainty of early April. The stock itself is broadly unchanged on the month at $84.17, down just 0.1%, though it gained 0.8% on the week. The last earnings print, in January, produced an 8% jump on the day and nearly 11% over the following five days — a move that may partly explain renewed call-side activity ahead of this quarter.
Short interest, meanwhile, offers little to excite either bears or squeeze-hunters. It eased roughly 8.5% in a single session on April 24 to 2.4% of the free float — well below the broader market's concern threshold and consistent with the view that CL is not a conviction short. Borrow costs have doubled over the past week to 0.51%, though that still puts them at historically low levels in absolute terms. Utilization has slipped back to just 1%, a fraction of its 52-week high of 3.93%, confirming ample room in the lending market.
The Street's debate reflects a genuine split on whether CL's pricing power can offset structural cost headwinds. The bull case centres on Colgate's advertising investment — up to 13.5% of sales in 2024 from 11.6% in 2021 — and the roughly 70% international revenue base that provides a growth runway from emerging markets. Morgan Stanley cut its target modestly to $95 last week while holding Overweight; JPMorgan similarly trimmed to $95 but maintained its positive stance. The consensus price target is around $95, implying about 13% upside to the current price. Bears focus on margin pressure: gross margins fell 75 basis points year-on-year in Q2 2025, raw material costs and tariffs are squeezing profitability, and Hill's Pet Nutrition — a key growth engine — recorded declining volumes in measured retail channels through the back half of 2025. Barclays sits at Equal-Weight with a $79 target, effectively the current price, signalling limited conviction on the upside case. The analyst rec differential scores in the 97th percentile, meaning consensus is constructive relative to peers, but target cuts have been the dominant theme across the board since early April.
The May 1 print is therefore a test of whether Colgate's organic volume trajectory has stabilised — and whether management can frame the tariff and commodity cost picture in a way that justifies the stock's trailing valuation of 21.6x earnings at a time when the broader consumer staples sector is under pressure.
See the live data behind this article on ORTEX.
Open CL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
